Zacks Small Cap Research – DYAI: Looking Toward Product Revenues – Go Health Pro
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the road, additional proteins may be added including bovine albumin, bovine transferrin … Read more
